Changes in the risk of death after HIV seroconversion compared with mortality in the general population

被引:339
作者
Bhaskaran, Krishnan [1 ]
Hamouda, Osamah [2 ]
Sannes, Mette [3 ]
Boufassa, Faroudy [4 ]
Johnson, Anne M. [5 ]
Lambert, Paul C. [6 ]
Porter, Kholoud [1 ]
机构
[1] MRC, Clin Trials Unit, London NW1 2DA, England
[2] Robert Koch Inst, D-1000 Berlin, Germany
[3] Ullevaal Univ Hosp, Oslo, Norway
[4] Hop Bicetre, INSERM, U822, Paris, France
[5] UCL, London, England
[6] Univ Leicester, Leicester, Leics, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2008年 / 300卷 / 01期
基金
英国医学研究理事会;
关键词
D O I
10.1001/jama.300.1.51
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Mortality among human immunodeficiency virus ( HIV) - infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population. Objective To evaluate changes in the mortality gap between HIV- infected individuals and the general uninfected population. Design, Setting, and Population Mortality following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts ( CASCADE) was compared with expected mortality, calculated by applying general population death rates matched on demographic factors. A Poisson- based model adjusted for duration of infection was constructed to assess changes over calendar time in the excess mortality among HIV-infected individuals. Data pooled in September 2007 were analyzed in March 2008, covering years at risk 1981- 2006. Main Outcome Measure Excess mortality among HIV- infected individuals compared with that of the general uninfected population. Results Of 16 534 individuals with median duration of follow- up of 6.3 years ( range, 1 day to 23.8 years), 2571 died, compared with 235 deaths expected in an equivalent general population cohort. The excess mortality rate ( per 1000 person- years) decreased from 40.8 ( 95% confidence interval [ CI], 38.5- 43.0; 1275.9 excess deaths in 31 302 person- years) before the introduction of highly active antiretroviral therapy ( pre- 1996) to 6.1 ( 95% CI, 4.8- 7.4; 89.6 excess deaths in 14 703 person- years) in 2004- 2006 ( adjusted excess hazard ratio, 0.05 [ 95% CI, 0.03- 0.09] for 2004- 2006 vs pre- 1996). By 2004- 2006, no excess mortality was observed in the first 5 years following HIV seroconversion among those infected sexually, though a cumulative excess probability of death remained over the longer term ( 4.8% [ 95% CI, 2.5%- 8.6%] in the first 10 years among those aged 15- 24 years). Conclusions Mortality rates for HIV- infected persons have become much closer to general mortality rates since the introduction of highly active antiretroviral therapy. In industrialized countries, persons infected sexually with HIV now appear to experience mortality rates similar to those of the general population in the first 5 years following infection, though a mortality excess remains as duration of HIV infection lengthens.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 29 条
[21]  
May M, 2007, AIDS, V21, P1185, DOI 10.1097/QAD.0b013e328133f285
[22]   Decline in the AIDS and death rates in the EuroSIDA study: an observational study [J].
Mocroft, A ;
Ledergerber, B ;
Katlama, C ;
Kirk, O ;
Reiss, P ;
Monforte, AD ;
Knsyz, B ;
Dietrich, M ;
Phillips, AN ;
Lundgren, JD .
LANCET, 2003, 362 (9377) :22-29
[23]  
Porter K, 2003, LANCET, V362, P1267, DOI 10.1016/S0140-6736(03)14570-9
[24]  
Porter K, 2000, AIDS, V14, P1899
[25]   Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy [J].
Rockstroh, JK ;
Mocroft, A ;
Soriano, V ;
Tural, C ;
Losso, MH ;
Horban, A ;
Kirk, O ;
Phillips, A ;
Ledergerber, B ;
Lundgren, J .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (06) :992-1002
[26]   Long-term survival in Hodgkin's disease patients: a comparison of relative survival in patients in trials and those recorded in population-based cancer registries [J].
Roy, P ;
Hudson, GV ;
Hudson, BV ;
Esteve, J ;
Swerdlow, AJ .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (03) :384-389
[27]   Older age and the response to and tolerability of antiretroviral therapy [J].
Silverberg, Michael J. ;
Leyden, Wendy ;
Horberg, Michael A. ;
DeLorenze, Gerald N. ;
Klein, Daniel ;
Quesenberry, Charles P., Jr. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (07) :684-691
[28]   Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-Infected individuals [J].
van Sighem, A ;
Danner, S ;
Ghani, AC ;
Gras, L ;
Anderson, RM ;
de Wolf, F .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (02) :212-218
[29]   Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study [J].
Viard, JP ;
Mocroft, A ;
Chiesi, A ;
Kirk, O ;
Roge, B ;
Panos, G ;
Vetter, N ;
Bruun, JN ;
Johnson, M ;
Lundgren, JD .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (08) :1290-1294